ORM 1 as a biomarker of increased vascular invasion and decreased sorafenib sensitivity in hepatocellular carcinoma. Biomol Biomed [Internet]. 2022 Oct. 23 [cited 2024 May 2];22(6):949-58. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/7268